Successful Treatment of an Elderly Patient With Combined Small Cell Lung Cancer Receiving Anlotinib: A Case Report

Combined small-cell lung cancer (C-SCLC) is a relatively rare subtype of SCLC and is defined by the combination of SCLC and any elements of non-small-cell lung carcinoma. Anlotinib is a novel oral multitarget tyrosine kinase inhibitor that led to significant improvements in progression-free survival...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yuying Gan, Pingli Liu, Tao Luo
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	combined small cell lung cancer elderly anlotinib long progression-free survival the first-line therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/41409f0333584d9694d76c723d7253b2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:41409f0333584d9694d76c723d7253b2
record_format	dspace
spelling	oai:doaj.org-article:41409f0333584d9694d76c723d7253b22021-11-11T06:46:30ZSuccessful Treatment of an Elderly Patient With Combined Small Cell Lung Cancer Receiving Anlotinib: A Case Report2234-943X10.3389/fonc.2021.775201https://doaj.org/article/41409f0333584d9694d76c723d7253b22021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.775201/fullhttps://doaj.org/toc/2234-943XCombined small-cell lung cancer (C-SCLC) is a relatively rare subtype of SCLC and is defined by the combination of SCLC and any elements of non-small-cell lung carcinoma. Anlotinib is a novel oral multitarget tyrosine kinase inhibitor that led to significant improvements in progression-free survival and overall survival in third-line therapy of advanced SCLC in the ALTER1202 study. Antiangiogenic therapy with anlotinib in C-SCLC has not previously been reported. An 80-year-old man was admitted with a 20-day history of blood-stained sputum. Chest computed tomography revealed a soft mass (45 × 43 mm) in the right upper lobe and a mediastinal lymph node and additional lung lesions in the homo lung. Pathology confirmed C-SCLC after an ultrasound-guided percutaneous puncture biopsy of the right lung tumor. The elderly patient was given anlotinib monotherapy at a dose of 10 mg/day on days 1–14 of a 21-day cycle after providing informed consent, and the outcome was assessed as continued partial response. As of the last follow-up evaluation, the patient’s progression-free survival was more than 7 months, and the treatment showed satisfactory safety. Our findings provide direct evidence of the efficacy of anlotinib in an elderly patient with C-SCLC. More studies are needed to confirm our observations.Yuying GanPingli LiuTao LuoFrontiers Media S.A.articlecombined small cell lung cancerelderlyanlotiniblong progression-free survivalthe first-line therapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	combined small cell lung cancer elderly anlotinib long progression-free survival the first-line therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	combined small cell lung cancer elderly anlotinib long progression-free survival the first-line therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Yuying Gan Pingli Liu Tao Luo Successful Treatment of an Elderly Patient With Combined Small Cell Lung Cancer Receiving Anlotinib: A Case Report
description	Combined small-cell lung cancer (C-SCLC) is a relatively rare subtype of SCLC and is defined by the combination of SCLC and any elements of non-small-cell lung carcinoma. Anlotinib is a novel oral multitarget tyrosine kinase inhibitor that led to significant improvements in progression-free survival and overall survival in third-line therapy of advanced SCLC in the ALTER1202 study. Antiangiogenic therapy with anlotinib in C-SCLC has not previously been reported. An 80-year-old man was admitted with a 20-day history of blood-stained sputum. Chest computed tomography revealed a soft mass (45 × 43 mm) in the right upper lobe and a mediastinal lymph node and additional lung lesions in the homo lung. Pathology confirmed C-SCLC after an ultrasound-guided percutaneous puncture biopsy of the right lung tumor. The elderly patient was given anlotinib monotherapy at a dose of 10 mg/day on days 1–14 of a 21-day cycle after providing informed consent, and the outcome was assessed as continued partial response. As of the last follow-up evaluation, the patient’s progression-free survival was more than 7 months, and the treatment showed satisfactory safety. Our findings provide direct evidence of the efficacy of anlotinib in an elderly patient with C-SCLC. More studies are needed to confirm our observations.
format	article
author	Yuying Gan Pingli Liu Tao Luo
author_facet	Yuying Gan Pingli Liu Tao Luo
author_sort	Yuying Gan
title	Successful Treatment of an Elderly Patient With Combined Small Cell Lung Cancer Receiving Anlotinib: A Case Report
title_short	Successful Treatment of an Elderly Patient With Combined Small Cell Lung Cancer Receiving Anlotinib: A Case Report
title_full	Successful Treatment of an Elderly Patient With Combined Small Cell Lung Cancer Receiving Anlotinib: A Case Report
title_fullStr	Successful Treatment of an Elderly Patient With Combined Small Cell Lung Cancer Receiving Anlotinib: A Case Report
title_full_unstemmed	Successful Treatment of an Elderly Patient With Combined Small Cell Lung Cancer Receiving Anlotinib: A Case Report
title_sort	successful treatment of an elderly patient with combined small cell lung cancer receiving anlotinib: a case report
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/41409f0333584d9694d76c723d7253b2
work_keys_str_mv	AT yuyinggan successfultreatmentofanelderlypatientwithcombinedsmallcelllungcancerreceivinganlotinibacasereport AT pingliliu successfultreatmentofanelderlypatientwithcombinedsmallcelllungcancerreceivinganlotinibacasereport AT taoluo successfultreatmentofanelderlypatientwithcombinedsmallcelllungcancerreceivinganlotinibacasereport
_version_	1718439393616723968

Successful Treatment of an Elderly Patient With Combined Small Cell Lung Cancer Receiving Anlotinib: A Case Report

Ejemplares similares